购物车
- 全部删除
- 您的购物车当前为空
TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).
TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 19,400 | 10-14周 | |
50 mg | ¥ 25,800 | 10-14周 | |
100 mg | ¥ 33,500 | 10-14周 |
产品描述 | TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP). |
靶点活性 | NEP:9.2(pIC50), AT1:(pKi)8.9 |
体外活性 | TD-0212 provides the enhanced activity of dual AT1/NEP inhibition and may have a lower risk of angioedema than dual ACE/NEP inhibition. |
体内活性 | In renin-dependent and non-dependent hypertension models, TD-0212 can lower blood pressure, similar to omapatrilat and the combination of AT1 receptor antagonist and NEP inhibitor. |
分子量 | 641.67 |
分子式 | C30H35F4N3O6S |
CAS No. | 1073549-11-7 |
密度 | 1.31g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 125 mg/mL (194.80 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容